Literature DB >> 7508325

Inhibition by rapamycin of leukocyte migration and bronchial hyperreactivity induced by injection of Sephadex beads to guinea-pigs.

J Nogueira de Francischi1, D M Conroy, K Maghni, P Sirois.   

Abstract

1. The effect of rapamycin (0.001 to 5 mg kg-1) on the increased leukocyte counts in bronchoalveolar lavage (BAL) fluid and hyperreactivity of isolated bronchial strips to histamine and acetylcholine (ACh) was studied following the intravenous injection of Sephadex beads to guinea-pigs. 2. The intramuscular (i.m.) injection of rapamycin (0.012 to 5 mg kg-1) dose-dependently inhibited the increase in leukocyte counts in BAL fluid. Rapamycin (5 mg kg-1) reduced the numbers of eosinophils neutrophils, macrophages and lymphocytes in BAL fluid by 64, 55, 19 and 50% respectively. In addition, rapamycin (0.012 to 5 mg kg-1) significantly inhibited the Sephadex-induced hyperreactivity of bronchial tissue to both histamine and ACh. 3. At a dose of 0.001 mg kg-1, rapamycin did not significantly reduce leukocyte infiltration or bronchial hyperreactivity. 4. Cyclosporin (5 mg kg-1) significantly reduced both lymphocyte and eosinophil numbers in BAL fluid of Sephadex-injected guinea-pigs whereas dexamethasone (1 mg kg-1) significantly reduced lymphocyte numbers. Neither drug affected the bronchial hyperreactivity to histamine and ACh. 5. It is concluded that the new immunosuppressive drug, rapamycin, is a potent inhibitor of leukocyte migration and bronchial hyperreactivity observed following the intravenous injection of Sephadex beads to guinea-pigs. Rapamycin also appears to be more effective than cyclosporin or dexamethasone in reducing leukocyte counts and bronchial hyperreactivity in this model. 6. Our results suggest that inflammatory mechanisms which are inhibited by rapamycin may be important in the induction of Sephadex-induced hyperreactivity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7508325      PMCID: PMC2175880          DOI: 10.1111/j.1476-5381.1993.tb13973.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

Review 1.  Asthma. Role of T-lymphocytes and lymphokines.

Authors:  C J Corrigan; A B Kay
Journal:  Br Med Bull       Date:  1992-01       Impact factor: 4.291

2.  Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma.

Authors:  M Azzawi; B Bradley; P K Jeffery; A J Frew; A J Wardlaw; G Knowles; B Assoufi; J V Collins; S Durham; A B Kay
Journal:  Am Rev Respir Dis       Date:  1990-12

3.  Rapamycin for immunosuppression in organ allografting.

Authors:  R Y Calne; D S Collier; S Lim; S G Pollard; A Samaan; D J White; S Thiru
Journal:  Lancet       Date:  1989-07-22       Impact factor: 79.321

4.  Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.

Authors:  C Vézina; A Kudelski; S N Sehgal
Journal:  J Antibiot (Tokyo)       Date:  1975-10       Impact factor: 2.649

5.  Human recombinant lymphokines and cytokines induce pulmonary eosinophilia in the guinea pig which is inhibited by ketotifen and AH 21-132.

Authors:  M A Kings; I Chapman; A Kristersson; S Sanjar; J Morley
Journal:  Int Arch Allergy Appl Immunol       Date:  1990

6.  The effects of drugs on Sephadex-induced eosinophilia and lung hyper-responsiveness in the rat.

Authors:  B A Spicer; R C Baker; P A Hatt; S M Laycock; H Smith
Journal:  Br J Pharmacol       Date:  1990-12       Impact factor: 8.739

7.  Increased numbers of hypodense eosinophils in the blood of patients with bronchial asthma.

Authors:  T Fukuda; S L Dunnette; C E Reed; S J Ackerman; M S Peters; G J Gleich
Journal:  Am Rev Respir Dis       Date:  1985-11

8.  Antigen challenge induces pulmonary airway eosinophil accumulation and airway hyperreactivity in sensitized guinea-pigs: the effect of anti-asthma drugs.

Authors:  S Sanjar; S Aoki; A Kristersson; D Smith; J Morley
Journal:  Br J Pharmacol       Date:  1990-04       Impact factor: 8.739

9.  Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat.

Authors:  S M Stepkowski; H Chen; P Daloze; B D Kahan
Journal:  Transplantation       Date:  1991-01       Impact factor: 4.939

10.  Interstitial and free lung cells in acute inflammation in the guinea-pig.

Authors:  M C Snella; T Venaille; P Holt; R Rylander
Journal:  Agents Actions       Date:  1987-12
View more
  6 in total

1.  Kinetics of eosinophilia and eosinophil activation in the development of non-allergic bronchial hyperresponsiveness in guinea pigs injected with Sephadex beads.

Authors:  K Maghni; M J Simard; D Arseneault; P Sirois
Journal:  Inflammation       Date:  1996-10       Impact factor: 4.092

2.  Early bronchial hyperresponsiveness following injection of sephadex beads in the guinea pig: involvement of platelet activating factor and thromboxane A2.

Authors:  D M Conroy; P Sirois
Journal:  Inflammation       Date:  1999-10       Impact factor: 4.092

3.  Effect of tumor necrosis factor receptor binding protein on cell infiltration induced by lipopolysaccharide and Sephadex beads in guinea pig lung.

Authors:  D M Conroy; J N Francischi; P Sirois
Journal:  Inflammation       Date:  1995-04       Impact factor: 4.092

4.  Effects of immunomodulators on airways hyperresponsiveness to adenosine induced in actively sensitised Brown Norway rats by exposure to allergen.

Authors:  Bruno Tigani; Jason P Hannon; Elisabeth Schaeublin; Lazzaro Mazzoni; John R Fozard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-06-24       Impact factor: 3.000

5.  Lung eosinophilia is dependent on IL-5 and the adhesion molecules CD18 and VLA-4, in a guinea-pig model.

Authors:  A M Das; T J Williams; R Lobb; S Nourshargh
Journal:  Immunology       Date:  1995-01       Impact factor: 7.397

6.  Effects of dexamethasone and cyclosporin A on the accumulation of eosinophils in acute cutaneous inflammation in the guinea-pig.

Authors:  M M Teixeira; T J Williams; P G Hellewell
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.